Skip to main content
. 2014 Mar 23;2014:704395. doi: 10.1155/2014/704395

Figure 1.

Figure 1

(a) Levels of anti-Beta 2 Glycoprotein I antibodies (aB2PGI) in controls (gray) and C-APS patients (white). (b) Levels of anticardiolipin antibodies (aCL) in controls (gray) and C-APS patients (white). Cutoff is indicated by a dotted line.